Testing and Diagnostics Library
Every article, presentation, spotlight, and news item we've tagged to Testing and Diagnostics.
Showing 49–72 of 314
Biomarker Competition Model Standardizes Aging Measurement
A competitive framework for validating aging biomarkers has been established to move beyond fragmented research and identify reproducible, clinically relevant measures of biological age. This standardized approach addresses a critical gap: aging research has accumulated numerous candidate biomarkers without consensus on which predict functional decline or lifespan with sufficient accuracy for clinical application.
An Extracellular Matrix Aging Clock Based on Circulating Matrisome Proteins Predicts Biological Aging and Disease
Researchers developed a 14-protein aging clock from circulating extracellular matrix proteins that predicts biological age, distinguishes healthy from diseased states, and responds to rejuvenation interventions. This identifies ECM remodeling as a measurable biomarker and potential therapeutic target for age-related decline.
Multi‐Omics Signatures of Organ Clocks in Biological Aging and Disease: A Conceptual Framework for Organ‐Specific Aging Clocks
Organ-specific aging clocks that integrate multiple molecular data types—genomics, epigenomics, transcriptomics, proteomics, and metabolomics—provide more accurate assessment of biological aging than single-measure approaches. This framework recognizes that individual organs age at different rates, offering a pathway to predict organ-specific disease risk and progression with greater precision.
Aging Clocks Measure Change, Not Functional Improvement
Aging clocks measure biological change but do not indicate whether that change improves tissue function or disease outcomes. The field must distinguish between biomarkers that correlate with aging and interventions that produce meaningful clinical benefit.
Genetic Testing Strategy: When Results Drive Real Health Changes
Genetic testing offers measurable clinical value when deployed strategically for risk stratification and actionable intervention, but its utility depends entirely on test selection, clinical context, and thoughtful interpretation of results. Random testing without a clear hypothesis or intervention pathway generates noise rather than insight.
Longitudinal changes in epigenetic clocks predict survival in the InCHIANTI cohort
Longitudinal acceleration in epigenetic clocks—independent of baseline epigenetic age—predicts mortality risk in the InCHIANTI cohort. The rate of change in multiple epigenetic clocks emerges as a more predictive mortality marker than epigenetic age alone, offering refined mortality risk stratification.
Biochemical phenotypes stratify aging risk independent of age
Older adults cluster into distinct biochemical phenotypes that predict divergent aging trajectories independent of chronological age. These latent patterns—identifiable through biomarker profiling—stratify risk for age-related decline and enable targeted intervention before clinical symptoms emerge.
Organ-specific aging clocks detect system decline before whole-body decline
Biological aging clocks have evolved from whole-body measures to organ-specific readouts that integrate molecular and imaging data, revealing that organs age at different rates within the same individual. This granularity shifts how we detect and potentially intervene in age-related decline across physiological systems.
Epigenetic Clocks of Biological Aging and Risk of Incident Mild Cognitive Impairment and Dementia: The Women's Health Initiative Memory Study
Accelerated biological aging measured by the epigenetic clock AgeAccelGrim2 was associated with increased risk of mild cognitive impairment and dementia in 6,069 cognitively unimpaired women over 9.3 years of follow-up, independent of chronological age. This establishes epigenetic markers as measurable indicators of neurodegeneration risk.
Multi-Omics Aging Clocks: Measuring Damage vs. Adaptation
Multi-omics aging clocks integrate epigenetic, transcriptomic, proteomic, metabolic, and microbial data to quantify biological age with greater accuracy than single-omics models, offering improved risk stratification for preventive medicine. The critical gap lies not in measurement precision but in distinguishing pathological damage from adaptive remodeling—a distinction that determines which interventions will meaningfully slow aging.
Multi-night sleep apnea testing captures respiratory patterns clinic studies miss
Sunrise Air, an FDA-cleared rechargeable at-home sleep testing device, enables multi-night monitoring of sleep apnea through lightweight chin sensors and airflow tracking, addressing diagnostic barriers that delay identification of a condition affecting over 900 million people globally. Accurate, accessible sleep apnea diagnosis has become central to longevity medicine because chronic sleep disruption directly drives cardiovascular disease, metabolic dysfunction, and accelerated aging.
SimonMed’s AI imaging expansion targets silent diseases
SimonMed is embedding FDA-cleared AI tools into routine imaging scans to detect silent diseases—cardiovascular disease, bone loss, spinal degeneration—earlier, without additional radiation or scan time. This shifts healthcare from reactive treatment to early detection by extracting actionable insights from imaging data already being captured.
scAgeClock: a single-cell transcriptome-based human aging clock model using gated multi-head attention neural networks
Researchers developed scAgeClock, a machine learning model that measures aging at the single-cell level by analyzing gene expression patterns. This cellular-resolution aging clock offers a novel method to detect age-related changes before systemic symptoms emerge, with potential applications in monitoring intervention efficacy and identifying individuals at accelerated aging risk.
AI-Accelerated Drug Discovery Narrows Path to Therapeutic Innovation
Insilico Medicine is advancing AI-driven pharmaceutical research through foundation models and specialized scientific agents designed to accelerate drug discovery. This represents a shift toward automated systems that could compress development timelines and expand the chemical and biological space available for therapeutic intervention.
Alnylam advances ATTR-CM detection with Viz.ai and AHA support
Alnylam is implementing AI-enabled diagnostic pathways and clinical learning collaboratives to accelerate detection of transthyretin-mediated amyloid cardiomyopathy (ATTR-CM), a progressive cardiac condition often diagnosed late. Earlier detection of this condition directly impacts treatment outcomes and disease trajectory, making systematic screening improvements clinically significant.
AI sharpens Alzheimer’s PET readouts
An artificial intelligence framework called interpretable adversarial decomposition learning (ADL) improves the clinical utility of Alzheimer's PET scans by filtering noise from disease signal, producing an ADAD score that correlates more closely with cognitive decline and neurodegeneration than traditional scoring methods. This advancement addresses a persistent gap between imaging findings and actual patient outcomes.
Traditional Risk Factors Outperform Epigenetic Clocks
Traditional risk factors—age, sex, smoking, alcohol consumption, waist-to-hip ratio, and BMI—predict chronic disease incidence more accurately than epigenetic clocks in middle-aged adults over 7–9 years. This finding challenges the clinical utility of epigenetic aging biomarkers without demonstrated incremental value over conventional assessment.
Syndex Bio’s mcPCR opens new path for early disease detection
Syndex Bio's mcPCR technology preserves DNA methylation patterns during amplification, enabling detection of disease-associated epigenetic changes from minimal samples. This advance addresses a critical gap in early disease detection and biological age assessment, with implications spanning oncology, prenatal diagnostics, and longevity research.
Executive Health program condenses three months of testing into six hours
Biograph's Executive Physical consolidates comprehensive cardiovascular, metabolic, cancer, and neurological screening into a single six-hour appointment using whole-body MRI, advanced CT, and biomarker analysis. This integrated approach identifies significant health findings in approximately 17 percent of participants and demonstrates measurable metabolic improvements in follow-up assessments.
AI, genomics and CRISPR signal a new phase of biological innovation
AI-driven pattern recognition combined with expanded genomic sequencing and CRISPR gene editing is accelerating drug discovery and precision medicine by generating large datasets for machine learning models. This convergence enables shorter development cycles and more targeted therapeutic interventions based on individual genetic profiles.
Human brain aging decoded through living tissue
Researchers mapped how living human brain cells coordinate structural changes across the lifespan, revealing that brain aging is an active, regulated biological process rather than passive deterioration. This represents the first large-scale analysis of living tissue, enabling identification of molecular targets for intervention in age-related neurological decline.
AI app puts longevity data in your pocket
Human Longevity has launched a mobile application that consolidates clinical data, biomarkers, genetic information, and imaging results into a continuous health record accessible to users. The platform uses AI to identify patterns across longitudinal data, shifting preventive health assessment from episodic annual checkups to real-time risk monitoring and interpretation.
Ultrasound Body Scanning Shifts From Clinic to Wellness Spa
Midjourney is developing whole-body scanning technology integrated into wellness spa environments, positioning routine body composition mapping as an accessible alternative to hospital-based imaging. The approach reflects a fundamental shift in how longevity-focused health systems are designed—moving from intervention-triggered testing to continuous, low-friction monitoring.
AI-Powered Diagnostics for Women Integrate Biology's Hidden Patterns
Xella Health launched an AI-powered diagnostic platform for women's health with 15,000 women already enrolled, addressing a critical gap in precision diagnosis by integrating genetic, proteomic, hormonal, and lifestyle data to assess risk across 130+ female-specific conditions. The platform reflects accelerating demand for diagnostic frameworks that explain symptom origins rather than simply managing them.